LQDA | Liquidia Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	9.76 - 10.44
52 Week Range	5.71 - 16.99
Beta	0.60
Implied Volatility	67.41%
IV Rank	17.85%
Day's Volume	984,839
Average Volume	1,239,682
Shares Outstanding	83,254,400
Market Cap	832,544,000
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-07-26

Valuation
Profitability
Growth
Health
P/E Ratio	-6.33
Forward P/E Ratio	-5.83
EPS	-1.58
1YR Price Target	13.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	145
Country	USA
Website	LQDA

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.

LQDA's peers: BMRN, JAZZ, PCVX, LEGN, TECH, UTHR, GERN, NRXP, AGEN, REPL, NVCT, LYRA, KRON, GOSS, TERN, AMLX, ABOS, INZY, XFOR, IMCR, MIRM, LRMR, KALV, MNKD, VNDA

*Chart delayed

Analyzing fundamentals for LQDA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see LQDA Fundamentals page.

Watching at LQDA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on LQDA Technicals page.